MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/apt.17967

Медицинская библиотека · Alimentary pharmacology & therapeutics · 2024

Review article: New developments in biomarkers and clinical drug development in alpha-1 antitrypsin deficiency-related liver disease.

Loomba Rohit, Clark Ginger, Teckman Jeff, Ajmera Veeral, Behling Cynthia, Brantly Mark, Brenner David, D'Armiento Jeanine, Fried Michael W, Iyer Janani S, Mandorfer Mattias, Rockey Don C, Tincopa Monica, Vuppalanchi Raj, Younossi Zobair, Krag Aleksander, Turner Alice M, Strnad Pavel

СтатьяОбзорПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Alpha-1 antitrypsin liver disease (AATLD) occurs in a subset of patients with alpha-1 antitrypsin deficiency. Risk factors for disease progression and specific pathophysiologic features are not well known and validated non-invasive assessments for disease severity are lacking. Currently, there are no approved treatments for AATLD.

AIMS: To outline existing understanding of AATLD and to identify knowledge gaps critical to improving clinical trial design and development of new treatments.

METHODS

This report was developed following a multi-stakeholder forum organised by the Alpha-1 Antitrypsin Deficiency Related Liver Disease Expert Panel in which experts presented an overview of the available literature on this topic.

RESULTS

AATLD results from a 'gain of toxic function' and primarily manifests in those with the homozygous Pi*ZZ genotype. Accumulation of misfolded 'Z' AAT protein in liver cells triggers intracellular hepatocyte injury which may ultimately lead to hepatic fibrosis. Male gender, age over 50 years, persistently elevated liver tests, concomitant hepatitis B or C virus infection, and metabolic syndrome, including obesity and type 2 diabetes mellitus, are known risk factors for adult AATLD. While the gold standard for assessing AATLD disease activity is liver histology, less invasive measures with low intra- and inter-observer variability are needed. Measurement of liver stiffness shows promise; validated thresholds for staging AATLD are in development. Such advances will help patients by enabling risk stratification and personalised surveillance, along with streamlining the development process for novel therapies.

CONCLUSIONS

This inaugural forum generated a list of recommendations to address unmet needs in the field of AATLD.

Для цитирования: Loomba Rohit, Clark Ginger, Teckman Jeff, Ajmera Veeral, Behling Cynthia, Brantly Mark, Brenner David, D'Armiento Jeanine, Fried Michael W, Iyer Janani S, Mandorfer Mattias, Rockey Don C, Tincopa Monica, Vuppalanchi Raj, Younossi Zobair, Krag Aleksander, Turner Alice M, Strnad Pavel. Review article: New developments in biomarkers and clinical drug development in alpha-1 antitrypsin deficiency-related liver disease.. Alimentary pharmacology & therapeutics. 2024. DOI: 10.1111/apt.17967.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.